Department of Public Health, Aichi Medical University School of Medicine, Aichi, Japan.
Department of Epidemiology and Preventive Medicine, Gifu University Graduate School of Medicine, Gifu, Japan.
Jpn J Clin Oncol. 2021 Jul 1;51(7):1158-1170. doi: 10.1093/jjco/hyab055.
In Japan, there are ongoing efforts to shift the gastric cancer prevention and control policy priorities from barium-based screening to Helicobacter pylori (H. pylori)-oriented primary prevention. A comprehensive summary of the evidence regarding the effects of H. pylori eradication on the risk of gastric cancer could inform policy decisions.
We conducted a systematic review and meta-analysis of published studies evaluating the effectiveness of H. pylori eradication for the prevention of gastric cancer in otherwise healthy individuals (primary prevention) and early gastric cancer patients (tertiary prevention).
In total, 19 studies were included. Three moderate-quality observational cohort studies showed that H. pylori eradication may be associated with a decreased risk of gastric cancer in healthy asymptomatic Japanese people. There is moderate certainty regarding the effectiveness of H. pylori eradication in patients with gastrointestinal diseases, such as peptic ulcers. A meta-analysis of 10 observational studies with otherwise healthy individuals (mainly peptic ulcer patients) yielded an overall odds ratio of 0.34 (95% CI: 0.25-0.46). Regarding tertiary prevention, the overall odds ratio for developing metachronous gastric cancer was 0.42 (95% CI: 0.35-0.51) in the eradication group in a meta-analysis of nine studies involving early gastric cancer patients who underwent endoscopic resection.
H. pylori eradication is effective in preventing gastric cancer in the Japanese population, regardless of symptoms. Well-designed, large cohort studies are warranted to determine the long-term efficacy and safety of H. pylori eradication in the context of reducing the gastric cancer burden through population-based screening and treatment.
在日本,人们正在努力将胃癌防控政策重点从基于钡的筛查转向以幽门螺杆菌(H. pylori)为导向的一级预防。综合总结有关 H. pylori 根除对胃癌风险影响的证据,可以为政策决策提供信息。
我们对评估健康人群(一级预防)和早期胃癌患者(三级预防)中 H. pylori 根除对胃癌预防效果的已发表研究进行了系统评价和荟萃分析。
共纳入 19 项研究。三项中等质量的观察性队列研究表明,H. pylori 根除可能与日本无症状健康人群胃癌风险降低相关。对于有胃肠道疾病(如消化性溃疡)的患者,H. pylori 根除的有效性存在中等确定性。对 10 项针对健康个体(主要是消化性溃疡患者)的观察性研究进行荟萃分析,得出总体比值比为 0.34(95%CI:0.25-0.46)。关于三级预防,对接受内镜下切除的早期胃癌患者的 9 项研究进行荟萃分析,根除组发生异时性胃癌的总体比值比为 0.42(95%CI:0.35-0.51)。
无论有无症状,H. pylori 根除在日本人群中预防胃癌均有效。需要设计良好的大型队列研究来确定 H. pylori 根除在通过人群筛查和治疗来降低胃癌负担方面的长期疗效和安全性。